The thrombin in Thrombin, Topical (Bovine Origin) THROMBIN-JMI® is a protein substance produced through a conversion reaction in which prothrombin of bovine origin is activated by tissue thromboplastin of bovine origin in the presence of calcium chloride. It is supplied as a sterile powder that has been freeze-dried in the final container. Also contained in the preparation are mannitol and sodium chloride. Mannitol is included to make the dried product friable and more readily soluble. The material contains no preservative.
THROMBIN-JMI® is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible.
In various types of surgery, solutions of THROMBIN-JMI® may be used in conjunction with an Absorbable Gelatin Sponge, USP for hemostasis, or any medical device approved by FDA for an indicated use with a specified, approved dosage of Thrombin, Topical (Bovine Origin).
Published Studies Related to Thrombin-JMI (Thrombin Topical)
Is there evidence that fresh frozen plasma is superior to antithrombin
administration to treat heparin resistance in cardiac surgery? 
A best evidence topic in cardiac surgery was written according to a structured
protocol. The question addressed was, 'in [patients with heparin resistance] is
[treatment with FFP] superior [to antithrombin administration] in [achieving
adequate anticoagulation to facilitate safe cardiopulmonary bypass]?' More than
29 papers were found using the reported search, of which six represented the best
evidence to answer the clinical question...
Thrombin generation mediators and markers in sepsis-associated coagulopathy and
their modulation by recombinant thrombomodulin. 
Severe sepsis remains the most common cause of death in critically ill patients,
and thrombin plays a crucial role in the pathogenesis of sepsis-associated
disseminated intravascular coagulation (DIC). The purpose of this study was to
profile prothrombin fragment (F1.2), thrombin-antithrombin complex (TAT), and
d-dimer (DD) throughout the course of hospital stay in patients identified with
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist
for clinical event reduction in acute coronary syndrome (TRA┬ĚCER) trial. 
CONCLUSION: The PAR-1 antagonist vorapaxar was associated with a reduction of MI,
Discovery and clinical evaluation of
enylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine
P1 motif. 
We have identified RWJ-671818 (8) as a novel, low molecular weight, orally active
inhibitor of human alpha-thrombin (K(i) = 1.3 nM) that is potentially useful for
the acute and chronic treatment of venous and arterial thrombosis. In a rat deep
venous thrombosis model used to assess antithrombotic efficacy, oral
administration of 8 at 30 and 50 mg/kg reduced thrombus weight by 87 and 94%,
A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. [2009.04]
BACKGROUND: Topical bovine thrombin has been used to accelerate attainment of hemostasis in the surgical setting for >60 years, and its immunogenicity has been widely reported. Although the development of antibodies is inherent in the introduction of any non-self-therapeutic protein such as bovine-sourced thrombin, there are questions about the relationship between the presence of antibodies to constituents of the therapeutic protein preparation and the occurrence of clinically relevant adverse events (AEs). OBJECTIVE: This review examines the proposed mechanisms for the immunogenicity of topical bovine thrombin preparations and summarizes available evidence from randomized clinical trials, observational studies, and case reports to explore possible relationships between the reported immunogenicity of topical bovine thrombin and the occurrence of AEs... CONCLUSIONS: Repeated perioperative exposure to topical bovine thrombin may increase both the prevalence and titers of antibodies to >or=1 protein contained in nonhomogeneous topical bovine thrombin preparations. However, the evidence reviewed does not support a definitive association between preoperative or postoperative generation of anti-bovine protein antibodies and an increased risk of AEs in surgical patients treated with topical bovine thrombin.
Clinical Trials Related to Thrombin-JMI (Thrombin Topical)
Study of Recombinant Human Thrombin for Bleeding During Surgery [Completed]
The purpose of this study is to determine whether recombinant human Thrombin (rhThrombin) is
effective in stopping bleeding during surgery, in comparison with bovine thrombin.
A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery [Completed]
The purpose of this study is to see if Human Thrombin is as effective as Bovine Thrombin in
stopping surgical bleeding within 10 minutes of application.
Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis [Recruiting]
Epistaxis is a common problem among people of all ages and backgrounds. However,
occasionally epistaxis can be severe enough to require emergency room admission. Among the
treatment options for epistaxis, nasal packing is the most common approach. This approach
requires a return visit to the clinic for removal of the packing. Additionally, there is a
great deal of pain during the insertion and removal of this packing. This study aims to
justify the further investigation of thrombin as a potential treatment approach for these
patients. Thrombin could provide a treatment approach that reduces pain and eliminates the
need for a return visit to the clinic.
Observational Study Assessing the Impact of Exposure to THROMBIN-JMI« on Coagulation Parameters. [Recruiting]
The purpose of this study is to assess the effect of possible exposure to THROMBIN JMI« on
activated partial thromboplastin time (aPTT) at 48 hours post surgery in subjects with
likelihood of prior exposure to THROMBIN JMI« within the past 4 years.
Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass [Recruiting]
Reports of Suspected Thrombin-JMI (Thrombin Topical) Side Effects
Postoperative Wound Infection (1),
Medication Error (1),
Adverse Event (1),
Circumstance or Information Capable of Leading TO Medication Error (1),
Factor V Inhibition (1), more >>
Page last updated: 2014-12-01